Nkarta, Inc. (NKTX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.84

From 52W high−52.32%

Volume1.44M

Market cap$125.34M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.84

From 52W high

−52.32%

Volume

1.44M

Market cap

$125.34M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

20.5

MomentumView details →

1D Return

−2.78%

YTD Return

−3.24%

SummaryUpdated Jun 1, 2026

Nkarta, Inc. (NASDAQ:NKTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in South San Francisco, California. The company went public in July 2020 and focuses on developing innovative cell therapies for cancer treatment using engineered natural killer (NK) cells. Nkarta represents part of the emerging field of cellular immunotherapy, where immune cells are modified to better recognize and attack cancer cells.

Ask drillr about Nkarta, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−47.36%

ROA (TTM)

−34.75%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−6.08%

FCF YoY

+6.28%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+11.88%

EBITDA YoY

+2.01%

MomentumView details →

1D Return

−2.78%

YTD Return

−3.24%

1Y Return

−26.64%

RSI (14)

20.5

vs 50D SMA

−30.33%

vs 200D SMA

−29.76%

Capital & dividendView details →

Debt/Equity

0.30x

Current Ratio

7.98x

Quick Ratio

7.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.54

EPS Surprise

−49.87%

Beats (12Q)

8/12

Next Q EPS Est

−$0.39

Avg Surprise (4Q)

−11.04%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−117.32M

Op. CF (TTM)

−92.76M

Next earningsNov 10, 2026 →

Latest newsMore news →

Nkarta reported a wider net loss of $40.37 million for Q2 2026, compared to $22.98 million in the prior-year quarter, due to higher operating expenses and lower other income.70d ago

Similar companies

Voyager Therapeutics, Inc.VYGR AN2 Therapeutics, Inc.ANTX Acumen Pharmaceuticals, Inc.ABOS Tiziana Life Sciences LtdTLSA Avidity Biosciences, Inc.RNA Outlook Therapeutics, Inc.OTLK Find similar companies →

Latest newsMore news →

Nkarta reported a wider net loss of $40.37 million for Q2 2026, compared to $22.98 million in the prior-year quarter, due to higher operating expenses and lower other income.70d ago